By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Janssen Pharmaceutica N.V. et al. v. Sandoz, Inc.
1:08-cv-00511; filed August 13, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 4,663,318 ("Method of Treating Alzheimer's Disease," issued May 5, 1987) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Janssen's Razadyne® (formerly Reminyl®) (galantamine hydrobromide, used to treat mild to moderate dementia of the Alzheimer's type). View the complaint here.
Hoffmann-La Roche Inc. v. Teva Pharmaceuticals USA, Inc. et al.
2:08-cv-04059; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche Inc. v. Orchid Chemicals & Pharmaceuticals Ltd. et al.
2:08-cv-04051; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche Inc. v. Apotex Inc. et al.
2:08-cv-04053; filed August 12, 2008 in the District Court of New Jersey
Hoffmann-La Roche Inc. v. Dr. Reddy's Laboratories, Ltd. et al.
2:08-cv-04055; filed August 12, 2008 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 7,410,957 ("Method of Treatment Using Bisphosphonic Acid," issued August 12, 2008) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Roche's Boniva® (150 mg once-monthly tablets) (ibandronate sodium, used to treat post-menopausal osteoporosis). View the Teva complaint here.
Aventis Pharma S.A. et al. v. Apotex Inc. et al.
1:08-cv-00496; filed August 8, 2008 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,714,512 ("Compositions Containing Taxane Derivatives," issued February 3, 1998) and 5,750,561 (same title, issued May 12, 1998) following a Paragraph IV certification as part of Apotex's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Aventis' Taxotere® (docetaxel, used to treat breast, lung, prostate, gastric, and head and neck cancers). View the complaint here.
Purdue Pharma Products LP et al. v. Impax Laboratories Inc.
1:08-cv-00502; filed August 8, 2008 in the District Court of Delaware
Infringement of U.S. Patent No. 6,254,887 ("Controlled Release Tramadol," issued July 3, 2001) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of plaintiffs' Ultram® ER (tramadol hydrochloride, used to treat moderate to moderately severe chronic pain). View the complaint here.
Biovail Laboratories International, SRL v. Sun Pharmaceutical Industries, Ltd., India
2:08-cv-04005; filed August 8, 2008 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,286,497 ("Diltiazem Formulation," issued February 15, 1994), 5,439,689 (same title, issued August 8, 1995), and 5,470,584 (same title, issued November 28, 1995) following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Biovail's Cardizem® CD (diltiazem, used to treat hypertension and for the management of chronic stable angina.). View the complaint here.
Takeda Pharmaceutical Company Limited et al. v. Mylan, Inc et al.
1:08-cv-06999; filed August 6, 2008 in the Southern District of New York
Infringement of U.S. Patent Nos. 5,965,584 ("Pharmaceutical Composition," issued October 12, 1999), 6,166,043 (same title, issued December 26, 2000), and 6,172,090 (same title, issued January 9, 2001) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Takeda's ACTOplus met® (pioglitazone and metformin, used an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes). View the complaint here.
Comments